Sopherion Therapeutics, Inc. Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
1/7/2010 10:29:14 AM
More...
|
Sopherion Therapeutics, Inc. Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3/18/2009 8:53:18 AM
More...
|
Sopherion Therapeutics, Inc. Announces Appointment of New Senior Executive Vice President for Clinical Affairs
2/24/2009 11:40:37 AM
More...
|
Sopherion Therapeutics, Inc. Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
2/5/2009 9:00:43 AM
More...
|
Sopherion Therapeutics, Inc. Raises $47 Million In Series B Funding And Acquires North American Rights To Myocet(R)
10/19/2005 5:11:33 PM
More...
|
Sprout Group Announces $12 Million Financing In Sopherion Therapeutics, Inc.
10/19/2005 5:10:55 PM
More...
|
Gunnar Casserstedt Joins Sopherion Therapeutics, Inc. As CFO
10/19/2005 5:09:43 PM
More...
|